Author: Romaniuk A1, Paszel-Jaworska A1, Totoń E1, Lisiak N1, Hołysz H1, Królak A1, Grodecka-Gazdecka S2, Rubiś B3
Affiliation: <sup>1</sup>Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, 49 Przybyszewskiego St., 60-355, Poznań, Poland. <sup>2</sup>Department of Oncology, Poznan University of Medical Sciences, Poznań, Poland. <sup>3</sup>Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, 49 Przybyszewskiego St., 60-355, Poznań, Poland. email@example.com.
Conference/Journal: Mol Biol Rep.
Date published: 2018 Nov 17
Other: Special Notes: doi: 10.1007/s11033-018-4496-x. [Epub ahead of print] , Word Count: 130
Telomerase is perceived as an immortality enzyme that enables passing the Hayflick limit. Its main function is telomere restoration but only in a limited group of cells, including cancer cells. Since it is found in a vast majority of cancer cells, it became a natural target for cancer therapy. However, it has much more functions than just altering the metabolism of telomeres-it also reveals numerous so-called non-canonical functions. Thus, a question arises whether it is always beneficial to turn it off when planning a cancer strategy and considering potential side effects? The purpose of this review is to discuss some of the recent discoveries about telomere-independent functions of telomerase in the context of cancer therapy and potential side effects.
KEYWORDS: Cancer; Telomerase; Telomeres; hTERT
PMID: 30448892 DOI: 10.1007/s11033-018-4496-x